| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C20H21F2N3O2S |
| Molar mass | 405.46 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CYM50308 (ML248) is a drug which acts as a selective agonist at the sphingosine-1-phosphate receptor S1PR4. It is used for research into the structure and function of the S1PR4 receptor, and has demonstrated potential applications for S1PR4 agonists in the treatment of asthma.[1][2][3]
References
[edit]- ^ Burkard T, Dreis C, Herrero San Juan M, Huhn M, Weigert A, Pfeilschifter JM, et al. (2021). "Enhanced CXCR4 Expression of Human CD8Low T Lymphocytes is Driven by S1P4". Frontiers in Immunology. 12 668884. doi:10.3389/fimmu.2021.668884. PMC 8421764. PMID 34504486.
- ^ Wang S, Tian Z, Lu Y, Huang Z, Fan Y, Li B, et al. (2023). "Sphingosine-1-Phosphate Receptor 4 Attenuates Neutrophilic Airway Inflammation in Experimental Asthma via Repressing Proinflammatory Macrophage Activation". International Journal of Biological Sciences. 19 (5): 1597–1615. doi:10.7150/ijbs.80256. PMC 10086758. PMID 37056936.
- ^ Wieczorek I, Strosznajder RP (2024). "S1P receptor modulators affect the toxicity of amyloid β oligomers in microglial and neuronal cells". Folia Neuropathologica. 62 (4): 348–361. doi:10.5114/fn.2024.145758. PMID 39963030.